

**REMARKS**

Prior to this Preliminary Amendment, Claims 1-23 as presented in the annex to the International Preliminary Examination Report were pending. With this Preliminary Amendment, Claims 6 and 11 have been amended and new Claim 24 has been added. Payment for the fees associated with the addition of these claims has been directed on the Transmittal Letter to the United States Designated/Elected Office Concerning a Filing Under 35 U.S.C. §371 filed concurrently herewith.

Respectfully submitted,

By: Karen L. Knezek  
Karen L. Knezek  
Registration No. 39,253

KLK:ld

14 January 2002

SIDLEY AUSTIN BROWN & WOOD LLP

717 N. Harwood, Suite 3400

Dallas, Texas 75201

(214) 981-3300

(214) 981-3400 (FAX)

**APPENDIX****VERSION WITH MARKINGS TO SHOW CHANGES MADE**

The following is a marked-up version of the changes to claims which are being made in the attached Preliminary Amendment. Added material is underlined, and deleted material is bracketed.

**IN THE CLAIMS**

6. The method of Claims 1, 2, 3[,] or 4[, 5], wherein said known anti-tumor composition is paclitaxel.

11. The method of Claims [7-11] 7, 8, 9 or 10, further comprising synthesizing said alternative composition.

24. The method of Claim 5, wherein said known anti-tumor composition is paclitaxel.